CDKN2A and glioblastoma: Although GBM is characterized by chromosome 10q loss, aberrant expression of proteins, such as epidermal growth factor receptor amplification and p16INK4a deletion, and gene mutations, such as TP53, IDH1, and PTEN, the molecular basis of the onset and progression of GBM malignancy is not fully understood [4, 5].